期刊文献+

苹果酸奈诺沙星胶囊治疗腹膜透析相关性导管感染的疗效分析 被引量:1

Efficacy of Nemonoxacin Malate capsule in the treatment of peritoneal dialysis-related catheter infection
原文传递
导出
摘要 目的 观察苹果酸奈诺沙星胶囊(Nemonoxacin Malate capsule)治疗腹膜透析相关性导管感染的疗效和安全性。方法 筛选2018-03-01—2021-12-31,中国医科大学附属第一医院腹膜透析中心腹膜透析外口感染、隧道感染使用苹果酸奈诺沙星胶囊治疗并规律随访的病例。收集患者基本资料,记录外口感染评分、感染相关指标,采用前后自身对照设计,回顾性分析腹膜透析相关性导管感染患者应用苹果酸奈诺沙星胶囊的治疗效果。结果 共纳入腹膜透析相关性导管感染应用苹果酸奈诺沙星胶囊的患者23例。23例患者发生29次导管感染,金黄色葡萄球菌是最主要致病菌(52.2%)。21例患者(91.3%)外口感染评分在应用苹果酸奈诺沙星胶囊后降至正常范围,2例患者(8.7%)治疗3周后外口感染评分仍未达标,23例患者(100%)外口感染评分均较用药前下降。所有患者均未出现严重不良事件。结论 苹果酸奈诺沙星胶囊治疗腹膜透析相关性导管感染安全有效。 Objective To observe the efficacy and safety of Nemonoxacin Malate capsule in the treatment of peritoneal dialysis-associated catheter infection. Methods Select cases receiving treatment from March 1,2018 to December 31,2021,who had suffered from peritoneal dialysis-associated exit-site infections or tunnel infections and received treatment of Nemonoxacin Malate capsules and regular follow-up in the Peritoneal Dialysis Center of the First Affiliated Hospital of China Medical University. The basic data of patients were collected to record the score of exit-site infection and infectionrelated indicators. The treatment effect on peritoneal dialysis associated catheter infection in patients taking Nemonoxacin Malate capsules was retrospectively analyzed through a before-and-after self-controlled design. Results A total of 23patients with peritoneal dialysis-related catheter infection were included,who were treated with Nemonoxacin Malate capsules. Totally 29 episodes of catheter infection occurred in 23 patients,and Staphylococcus aureus was the most predominant pathogen(52.2%). The score of exit-site infection of 21 patients(91.3%)decreased to the normal range after the application of Nemonoxacin Malate capsules,the score of two patients(8.7%)was still not up to the standard after three weeks of treatment with Nemonoxacin Malate capsules,and 23 patients(100%)had a lower score of exit-site infection than before the application of Nemonoxacin Malate capsules. All patients had no serious adverse reactions. Conclusion Nemonoxacin Malate capsule is safe and effective in the treatment of peritoneal dialysis-related catheter infection.
作者 肖一凡 朱新旺 徐春炎 韩莹雯 吴微 陈莹 孙亚南 姚丽 XIAO Yi-fan;ZHU Xin-wang;XU Chun-yan;HAN Ying-wen;WU Wei;CHEN Ying;SUN Ya-nan;YAO Li(Department of Nephrology,the First Affiliated Hospital of China Medical University,Shenyang 110001,China)
出处 《中国实用内科杂志》 CAS CSCD 北大核心 2024年第3期218-222,共5页 Chinese Journal of Practical Internal Medicine
基金 国家自然科学基金(82070763) 辽宁省重点研发指导计划(2020JH2/10300045)。
关键词 苹果酸奈诺沙星胶囊 腹膜透析 导管感染 Nemonoxacin Malate capsule peritoneal dialysis catheter infection
作者简介 通信作者:姚丽,电子信箱:liyao_cmu@163.com。
  • 相关文献

参考文献5

二级参考文献42

  • 1曹彩霞,刘飞燕,万珍,吕燕,梁艳琳.持续血液净化治疗肾功能障碍感染性休克的临床疗效评价[J].中国全科医学,2020(S01):177-178. 被引量:5
  • 2陈崴,姜宗培,郑勋华,陈伟英,郭群英,毛海萍,叶晓青,阳晓,余学清.腹膜透析置管术预防性抗生素用药的前瞻性随机对照临床研究[J].中华肾脏病杂志,2006,22(10):601-604. 被引量:11
  • 3冯敏,郭群英,余学清,陈冬梅,阳晓,姜宗培,毛海萍,陈崴,董秀清,傅君舟,李剑文,陈林.提高腹膜透析相关感染性腹膜炎致病菌培养阳性率的方法学研究[J].中华肾脏病杂志,2007,23(6):345-350. 被引量:15
  • 4黄伟,郭汉林.慢性肾功能衰竭维持性血液透析患者死因分析及防治措施[J].广东医学,2007,28(10):1681-1682. 被引量:11
  • 5Beth P, George R. Bailie, Judith Bernardini, et al. Peritoneal dialysis-related infections recommendations:2005 update [J]. Peritoneal Dialysis International, 2006,25: 107-131.
  • 6Judith B, Valerie P, Ana F, et al. ISPD guidelines/ recommendations: Peritoneal dialysis patient training[J]. Peritoneal Dialysis International, 2006;26:625-632.
  • 7Gokal R, Ash SR, Helfrich GB, et al. Peritoneal catheters and exit site practices: Toward optimum peritoneal access [J]. Perit Dial Int, 1993, 13: 29-39.
  • 8Golper TA, Brier ME, Bunke M, et al. Risk factors for peritonitis in long-term peritoneal dialysis: The Network 9 peritonitis and catheter survival studies[J]. Am J Kidney Dis, 1996, 28: 428-436.
  • 9Perez Fontan M, Garcia-Falcon T, Rosales M, et al, Treatment of Staphylococcus aureus nasal carriers in continuous ambulatory peritoneal dialysis with mupirocin: Long term results[J]. Am J Kidney Dis, 1993, 22: 708-712.
  • 10Schaefer F, Klaus G, Muller-Wiefel DE, et al. Intermittent versus continuous intraperitoneal glycopeptide/ceftazidime treatment in children with peritoneal dialysis-associated peritonitis. The Mid-European Pediatric Peritoneal Dialysis Study Group (MEPPS)[J]. J Am Soc Nephrol, 1999, 10 : 136-175.

共引文献176

同被引文献13

引证文献1

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部